Levofloxacin 500

PreclinicalSmall molecule

DDr. Reddy's Laboratories Limited

Levofloxacin 500 is one of 17 small molecule programs targeting Chronic Prostatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic ProstatitisActive, not recruiting

Chronic ProstatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Chronic Prostatitis

#DrugCompanyPhaseTrials

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 2

Uroxatral

AAdvanz Pharma

Phase 3

1 3

Avodart

Akero Therapeutics

Phase 3

1 4

Actimmune

HHorizon Therapeutics Ireland DAC

Thalomid

1 6

Cipro

Bayer

Phase 2

1 7

Rapaflo

AbbVie

Phase 2

1 8

OM-89

AAJU Pharm Co., Ltd.

Approved

1 9

Tamsulosin OCAS

Astellas

Phase 2

2 10

CC-10004

Amgen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Prostatitis1 trial

Non Interventional Study of Levofloxacin in Chronic Prostatitis

Completed·—··NCT02711943·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Levofloxacin 500. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levofloxacin 500 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levofloxacin 500. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr. Reddy's Laboratories Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDr. Reddy's Laboratories Limited

Levofloxacin 500

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Prostatitis1 trial

References

Drug Info

Quick Facts

Related News